BeStock  
Stocks › Drug Manufacturers - Specialty & Generic › BCRX

BioCryst Pharmaceuticals BCRX

US equityMarket cap rank #2750Drug Manufacturers - Specialty & Generic
$8.10 −$0.07 (-0.86%)
Pre-market · Oct 6, 7:30 am ET · After hours $8.10 0.00%
Open$8.17
Prev close$8.17
Day range$7.92 – $8.25
Volume4.71M
Market cap$2.07B
P/E (TTM)–
Dividend yield–

BCRX Stock News

Headlines matching BioCryst Pharmaceuticals or the BCRX ticker, most recent first.

  • Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16Market news · 9 Sep 2026
  • J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13Market news · 30 Sep 2026
  • RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11Market news · 10 Sep 2026
  • H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32Market news · 7 Aug 2026
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13Market news · 6 Aug 2026
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20Market news · 6 Aug 2026
  • TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30Market news · 6 Aug 2026
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14Market news · 7 Jul 2026
  • BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $15Market news · 15 Jul 2026
  • J.P. Morgan Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $12Market news · 13 Jul 2026
  • J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)TipRanks · 13 Jul 2026
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $21Market news · 13 Jul 2026
  • A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32Market news · 1 Jul 2026
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $21Market news · 8 May 2026
  • BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy RatingMarket news · 16 Apr 2026

Discussion

No comments yet — be the first to weigh in on BCRX.

Leave a comment

Scroll to Top